DY131

DY131 (GSK 9089) is a potent and selective ERRγ and ERRβ agonist. DY131displays inactive against ERRα, ERα and ERβ[1][2]. DY131 also inhibits Smo signaling[3].

Product Specifications

CAS Number

[95167-41-2]

Product Name Alternative

GSK 9089

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Estrogen Receptor/ERR; Smo

Type

Reference compound

Related Pathways

Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/DY131.html

Concentration

10mM

Purity

99.72

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N/N=C/C1=CC=C(N(CC)CC)C=C1)C2=CC=C(O)C=C2

Molecular Formula

C18H21N3O2

Molecular Weight

311.38

Precautions

H302, H312, H332

References & Citations

[1]Wang Y, et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation . ACS Chem Biol. 2012,15;7 (6) :1040-8.|[2]Yamamoto T, et al. Estrogen-related receptor-γ regulates estrogen receptor-α responsiveness in uterine endometrial cancer. Int J Gynecol Cancer. 2012;22 (9) :1509-16.|[3]Yu S, et al. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 2007;67 (10) :4904-14.|[4]Donna D. Yu, Barry Marc Forman. Identification of an agonist ligand for estrogen-related receptors ERRβ/γ. Bioorganic & Medicinal Chemistry Letters. 2005,15 (5) : 1311-1313.|[5]A Pacwa, et al. Interplay between estrogen-related receptors and steroidogenesis-controlling molecules in adrenals. In vivo and in vitro study. Acta Histochem. 2018 Jul;120 (5) :456-467.